127 related articles for article (PubMed ID: 2527769)
1. HLA and allopurinol drug eruption.
Chan SH; Tan T
Dermatologica; 1989; 179(1):32-3. PubMed ID: 2527769
[TBL] [Abstract][Full Text] [Related]
2. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.
Ng CY; Yeh YT; Wang CW; Hung SI; Yang CH; Chang YC; Chang WC; Lin YJ; Chang CJ; Su SC; Fan WL; Chen DY; Wu YJ; Tian YC; Hui RC; Chung WH;
J Invest Dermatol; 2016 Jul; 136(7):1373-1381. PubMed ID: 26996548
[TBL] [Abstract][Full Text] [Related]
3. Drug eruptions induced by allopurinol associated with HLA-B*5801.
Zeng M; Zhang M; Liu F; Yan W; Kong Q; Sang H
Indian J Dermatol Venereol Leprol; 2015; 81(1):43-5. PubMed ID: 25566896
[TBL] [Abstract][Full Text] [Related]
4. Human leukocyte antigens and drug hypersensitivity.
Chung WH; Hung SI; Chen YT
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
[TBL] [Abstract][Full Text] [Related]
5. HLA and antibiotic allergic skin eruption.
Chan SH; Tan T; Wee GB; Lim AY
Ann Acad Med Singap; 1988 Oct; 17(4):518-9. PubMed ID: 2975936
[TBL] [Abstract][Full Text] [Related]
6. Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.
Jarjour S; Barrette M; Normand V; Rouleau JL; Dubé MP; de Denus S
Pharmacogenomics; 2015; 16(7):755-67. PubMed ID: 25965122
[TBL] [Abstract][Full Text] [Related]
7. Fixed drug eruption in a patient of HLA-B*58:01 negative after allopurinol administration: A case report.
Zhang R; Geng H; Du J; Liu M
J Clin Pharm Ther; 2022 Jun; 47(6):841-843. PubMed ID: 35118681
[TBL] [Abstract][Full Text] [Related]
8. HLA and skin disease in the Chinese.
Chan SH
Ann Acad Med Singap; 1983 Jan; 12(1):3-5. PubMed ID: 6222684
[TBL] [Abstract][Full Text] [Related]
9. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.
Ko TM; Tsai CY; Chen SY; Chen KS; Yu KH; Chu CS; Huang CM; Wang CR; Weng CT; Yu CL; Hsieh SC; Tsai JC; Lai WT; Tsai WC; Yin GD; Ou TT; Cheng KH; Yen JH; Liou TL; Lin TH; Chen DY; Hsiao PJ; Weng MY; Chen YM; Chen CH; Liu MF; Yen HW; Lee JJ; Kuo MC; Wu CC; Hung SY; Luo SF; Yang YH; Chuang HP; Chou YC; Liao HT; Wang CW; Huang CL; Chang CS; Lee MT; Chen P; Wong CS; Chen CH; Wu JY; Chen YT; Shen CY;
BMJ; 2015 Sep; 351():h4848. PubMed ID: 26399967
[TBL] [Abstract][Full Text] [Related]
10. HLA-system in Chinese children with insulin-dependent diabetes mellitus: a strong association with DR3.
Lee BW; Chan SH; Tan SH; Wee GB; Yap HK; Wong HB; Tan CL; Tan KW
Metabolism; 1984 Dec; 33(12):1102-5. PubMed ID: 6334218
[TBL] [Abstract][Full Text] [Related]
11. A serological study of the HLA-B17 cross-reactive group.
Darke C
Tissue Antigens; 1984 Mar; 23(3):141-50. PubMed ID: 6203186
[TBL] [Abstract][Full Text] [Related]
12. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese.
Cao ZH; Wei ZY; Zhu QY; Zhang JY; Yang L; Qin SY; Shao LY; Zhang YT; Xuan JK; Li QL; Xu JH; Xu F; Ma L; Huang HY; Xing QH; Luo XQ
Pharmacogenomics; 2012 Jul; 13(10):1193-201. PubMed ID: 22909208
[TBL] [Abstract][Full Text] [Related]
13. Detection of HLA-B*58:01 with TaqMan assay and its association with allopurinol-induced sCADR.
Zhang X; Ma H; Hu C; Yu B; Ma W; Wu Z; Luo X; Zou H; Guan M
Clin Chem Lab Med; 2015 Feb; 53(3):383-90. PubMed ID: 25257159
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation.
Sukasem C; Puangpetch A; Medhasi S; Tassaneeyakul W
Asian Pac J Allergy Immunol; 2014 Jun; 32(2):111-23. PubMed ID: 25003724
[TBL] [Abstract][Full Text] [Related]
15. NEW STRATEGIES TO PREDICT AND PREVENT SERIOUS IMMUNOLOGICALLY MEDIATED ADVERSE DRUG REACTIONS.
Phillips EJ
Trans Am Clin Climatol Assoc; 2018; 129():74-87. PubMed ID: 30166701
[TBL] [Abstract][Full Text] [Related]
16. Allopurinol-induced severe cutaneous adverse reactions.
Campochiaro C
Ann Rheum Dis; 2016 Apr; 75(4):e20. PubMed ID: 26787371
[No Abstract] [Full Text] [Related]
17. An unusual cutaneous reaction secondary to allopurinol.
Raymond JZ; Goldman HM
Cutis; 1988 May; 41(5):323-6. PubMed ID: 2967161
[TBL] [Abstract][Full Text] [Related]
18. Allopurinol dose relative to renal function and risk of hypersensitivity reactions.
Day R; Hung SI; Chung WH
Ann Rheum Dis; 2016 Apr; 75(4):e21. PubMed ID: 26893486
[No Abstract] [Full Text] [Related]
19. Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions.
Chung WH; Pan RY; Chu MT; Chin SW; Huang YL; Wang WC; Chang JY; Hung SI
J Invest Dermatol; 2015 Sep; 135(9):2237-2248. PubMed ID: 25946710
[TBL] [Abstract][Full Text] [Related]
20. Severe drug eruptions revisited.
Calbo S
Immunol Res; 2012 Sep; 53(1-3):162-7. PubMed ID: 22407574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
